LED Medical Diagnostics Inc. Announces Appointment of Lamar Roberts to President of LED Dental Ltd.
BURNABY, British Columbia February 25, 2014 - LED Medical Diagnostics Inc. ("LED Medical" or the "Company") announced today that Mr. Lamar Roberts has accepted the role of President of LED Dental Ltd. ("LED Dental"), effective immediately.
Mr. Roberts joined LED Dental, a wholly-owned subsidiary of LED Medical, as the Vice President of Sales and Marketing in October 2013. "As Lamar embarked on his role as VP of Sales and Marketing, it became clear that his breadth of knowledge and leadership style could be effective across all functions of the organization," stated Dr. David Gane, CEO of LED Medical. "The Company is at an exciting juncture in its corporate growth and Lamar has the right background to guide it to international leadership."
Mr. Roberts has held Senior Executive positions with 360imaging, Carestream Dental and PracticeWorks and has developed an industry reputation for guiding companies from early growth stages to becoming industry giants. Mr. Roberts has an extensive background in mergers and acquisitions and proven record in leading commercial efforts in technical, medical, and geographically dispersed organizations. His overarching focus within LED Dental will be to execute on the Company's corporate growth strategies by actively expanding its sales footprint, creating opportunities for collaborative research partnerships, and evaluating new technology opportunities in the global marketplace.
"I have witnessed Lamars leadership capabilities and unwavering focus on growth during our tenure at Carestream Dental. Already, over the past 4 months, he has put into motion several initiatives for LED Dental which have fast tracked the Company's market expansion goals," states Dr. David Gane. "We are pleased that he will bring this vision, momentum and energy to his wider role as President of LED Dental."
About the VELscope® Vx Enhanced Oral Assessment System
The distinctive blue-spectrum light of the VELscope® Vx hand-held device causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, side-effects from medication, thermal damage, fungal, viral or bacterial infections. Use of the VELscope® Vx allows a wide variety of oral abnormalities to be discovered, often before they're visible to the unassisted eye. It is also the only tissue fluorescence device with photo/video documentation capabilities through the viewing mechanism, a key function for referrals and patient records.
Today VELscope® devices are used to conduct more examinations for oral cancer and other oral diseases than any other adjunctive device. To date, more than 13,000 VELscope® systems are in use globally and dental practitioners have performed more than 25 million exams.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.
Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.
For media or investor relations inquiries, please contact:
Forward Looking Statement
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future distribution strategy and product offering, and the potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies to the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.